Suitability-for-Use Considerations for Prefilled Syringes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Suitability-for-Use Considerations for Prefilled Syringes
The nature of their application and their mode of use mean that prefilled syringes meet the regulatory definitions of immediate packaging or container–closure systems.


Pharmaceutical Technology


13. A.S. Rosenberg and A.S. Worobec, "A Risk-Based Approach to Immunogenicity Concerns of Therapeutic Protein Products, Part 2: Considering Host-Specific and Product-Specific Factors Impacting Immunogenicity," BioPharm Int. 17 (12), 34–40 (2004).

14. I. Markovic, "Challenges Associated with Extractable and/or Leachable Substances in Therapeutic Biologic Protein Products," Am. Pharm. Rev. 9 (6), 20–27 (2006).

15. Z.Q. Wen et al., "Investigation of Contaminants in Protein Pharmaceuticals in Prefilled Syringes by Multiple Microspectroscopies," Am. Pharm. Rev. 10 (5), 101–107 (2007).

16. B. Sharma, "Immunogenicity of Therapeutic Proteins Part 2. Impact of Container Closures." Biotech. Adv. 25 (3), 318–324 (2007).

17. L.S. Jones, A. Kaufmann, and C.R. Middaugh, "Silicone Oil Induced Aggregation of Proteins," J. Pharm. Sci. 94 (4), 918–927 (2004).

18. D.E. Overcashier, E.K. Chan, and C.C. Hua, "Technical Considerations in the Development of Prefilled Syringes for Protein Products," Am. Pharm. Rev. 9 (7), 77–83 (2006).

19. B. Sharma et al., "Technical Investigations into the Cause of the Increased Incidence of Antibody-Mediated Pure Red Cell Aplasia Associated with Eprex," Eur. J. Hosp. Pharm. 5, 86–91 (2004).

20. K. Boven et al., "Epoetin-Associated Pure Red Cell Aplasia in Patients with Chronic Kidney Disease: Solving the Mystery," Nephr. Dialy. Trans. 20 (suppl. 3), ii30–ii40 (2005)

21. J. Pang et al., "Recognition and Identification of Leachables in EPREX Prefilled Syringes: An Unexpected Occurrence at a Formulation-Component Interface," PDA J. Pharm. Sci. Technol. 61 (6), 423–432 (2007).

For more on this topic, see "Big Shot: Developments in Prefilled Syringes" in the March 2007 issue of Pharmaceutical Technology.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
Source: Pharmaceutical Technology,
Click here